<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Objective - Patients presenting with <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> or <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">mood disorders</z:e> present with neuropsychological deficits such as executive and <z:e sem="disease" ids="C0233794" disease_type="Mental or Behavioral Dysfunction" abbrv="">memory disturbance</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Deficits of these functions have also been reported in patients presenting with alcohol use or <z:e sem="disease" ids="C0038586" disease_type="Mental or Behavioral Dysfunction" abbrv="AODD">substance use disorders</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>A large percentage of patients with non-affective <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> or <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">mood disorders</z:e> present with a comorbid <z:e sem="disease" ids="C0038586" disease_type="Mental or Behavioral Dysfunction" abbrv="AODD">substance use disorder</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>These subjects are often a priori excluded from most neuropsychological studies </plain></SENT>
<SENT sid="4" pm="."><plain>However, using such an exclusion criterion may induce a selection bias linked to the high prevalence of this <z:e sem="disease" ids="C0700319" disease_type="Mental or Behavioral Dysfunction" abbrv="MICA">dual diagnosis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>It is therefore necessary to further explore the impact of <z:e sem="disease" ids="C0740858" disease_type="Mental or Behavioral Dysfunction" abbrv="">substance abuse</z:e> on neuropsychological performance in subjects with <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> or <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">mood disorders</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Method - Patients consecutively hospitalized for a non-affective <z:e sem="disease" ids="C0033975" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychotic disorder</z:e> or a <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">mood disorder</z:e> were included </plain></SENT>
<SENT sid="7" pm="."><plain>A standardised method was used to collect information on addictive behaviour, clinical and social characteristics </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="4" ids="38624">DSM</z:chebi> IV diagnoses, including those of substance use, were made using a structured diagnostic interview and <z:hpo ids='HP_0000001'>all</z:hpo> other available clinical and historical information collected during the hospital stay </plain></SENT>
<SENT sid="9" pm="."><plain>Memory performance was tested using the Batterie d'Efficience Mn√©sique 84 (Battery of memory efficiency 84 items, BEM 84) </plain></SENT>
<SENT sid="10" pm="."><plain>Executive abilities were explored using the Wisconsin Card Sorting Test (WCST) and the Stroop test </plain></SENT>
<SENT sid="11" pm="."><plain>ANCOVAs with <z:e sem="disease" ids="C0006874" disease_type="Mental or Behavioral Dysfunction" abbrv="">cannabis use disorder</z:e> or <z:e sem="disease" ids="C0001956" disease_type="Mental or Behavioral Dysfunction" abbrv="">alcohol use disorder</z:e> as main factor were used to examine associations with neuropsychological test scores </plain></SENT>
<SENT sid="12" pm="."><plain>Results - We have included 77 patients fulfilling the diagnostic criteria for non-affective <z:e sem="disease" ids="C0033975" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychotic disorders</z:e> (<z:hpo ids='HP_0100753'>schizophrenia</z:hpo>, <z:e sem="disease" ids="C0036337" disease_type="Mental or Behavioral Dysfunction" abbrv="">schizoaffective disorder</z:e>, <z:e sem="disease" ids="C0011251" disease_type="Mental or Behavioral Dysfunction" abbrv="">delusional disorder</z:e>, other <z:e sem="disease" ids="C0033975" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychotic disorder</z:e>, n=35) or <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">mood disorders</z:e> (n=42) </plain></SENT>
<SENT sid="13" pm="."><plain>Among these patients, 27.3% presented with a lifetime history of <z:e sem="disease" ids="C0085762" disease_type="Mental or Behavioral Dysfunction" abbrv="aca">alcohol abuse</z:e>/dependence (current prevalence: 14.3%) and 23.4% presented with a lifetime history of <z:e sem="disease" ids="C0006868" disease_type="Disease or Syndrome" abbrv="">cannabis abuse</z:e>/dependence (current prevalence: 11.7%) </plain></SENT>
<SENT sid="14" pm="."><plain>We have assessed the specific impact of alcohol and cannabis use on neuropsychological performance </plain></SENT>
<SENT sid="15" pm="."><plain>No significant differences on memory and executive performance were found between patients presenting with and without a lifetime history of <z:e sem="disease" ids="C0085762" disease_type="Mental or Behavioral Dysfunction" abbrv="aca">alcohol abuse</z:e>/dependence </plain></SENT>
<SENT sid="16" pm="."><plain>These results were not modified after adjustement for potential confounding factors (age, gender, educational level, age at <z:hpo ids='HP_0003674'>onset</z:hpo>, diagnosis, current versus past addictive behaviour) </plain></SENT>
<SENT sid="17" pm="."><plain>Patients with a lifetime history of <z:e sem="disease" ids="C0006868" disease_type="Disease or Syndrome" abbrv="">cannabis abuse</z:e>/dependence had significantly higher (i.e. better performance) general BEM 84 score (F=3.89, df=1, p=0.05), higher complex figure delayed recall scores (F=6.62, df=1, p=0.01) and higher recognition scores (F=3.9, df=1, p=0.05) than patients presenting without a lifetime history of cannabis use </plain></SENT>
<SENT sid="18" pm="."><plain>After adjustment on covariables (age, gender, educational level, age at <z:hpo ids='HP_0003674'>onset</z:hpo>, diagnosis, current versus past addictive behaviour), the differences on memory performance between the two groups were no longer significant, the differences found before adjustment were mainly explained by the confounding effect of age </plain></SENT>
<SENT sid="19" pm="."><plain>Patients presenting with a lifetime history of <z:e sem="disease" ids="C0006868" disease_type="Disease or Syndrome" abbrv="">cannabis abuse</z:e>/dependence had significantly lower interference scores on the Stroop test than subjects without cannabis use (F=5.67, df=1, p=0.02) </plain></SENT>
<SENT sid="20" pm="."><plain>This finding was not modified after adjustment for confounding factors </plain></SENT>
<SENT sid="21" pm="."><plain>Information on substance use was collected by interviewing the patient and was completed by using <z:hpo ids='HP_0000001'>all</z:hpo> other available source of information, but no urine testing was performed </plain></SENT>
<SENT sid="22" pm="."><plain>Thus, substance use could have been underestimated or unrecognized in some patients </plain></SENT>
<SENT sid="23" pm="."><plain>We did not distinguish patients who presented with <z:e sem="disease" ids="C0740858" disease_type="Mental or Behavioral Dysfunction" abbrv="">substance abuse</z:e> from those who presented with dependence because there were few of the latter </plain></SENT>
<SENT sid="24" pm="."><plain>Distinguishing these two populations would be of interest because dependence may have a more deleterious effect than abuse in neuropsychological performances </plain></SENT>
<SENT sid="25" pm="."><plain>Finally, we did not included <z:mpath ids='MPATH_458'>normal</z:mpath> control subjects so we can not assess if our cohort present with memory and executive deficits compared to <z:mpath ids='MPATH_458'>normal</z:mpath> subjects </plain></SENT>
<SENT sid="26" pm="."><plain>Conclusion - Comorbid alcohol or <z:e sem="disease" ids="C0006868" disease_type="Disease or Syndrome" abbrv="">cannabis abuse</z:e>/dependence has limited effects on memory and executive abilities in subjects with <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> or <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">mood disorder</z:e> </plain></SENT>
<SENT sid="27" pm="."><plain>The only significant difference between subjects with and without a <z:e sem="disease" ids="C0700319" disease_type="Mental or Behavioral Dysfunction" abbrv="MICA">dual diagnosis</z:e> was that subjects with <z:e sem="disease" ids="C0006874" disease_type="Mental or Behavioral Dysfunction" abbrv="">cannabis use disorder</z:e> performed poorly on the Stroop test </plain></SENT>
<SENT sid="28" pm="."><plain>No other significant difference in executive and memory performance was found after adjustment for confounding factors </plain></SENT>
<SENT sid="29" pm="."><plain>Since there is a high prevalence of a comorbid <z:e sem="disease" ids="C0038586" disease_type="Mental or Behavioral Dysfunction" abbrv="AODD">substance use disorder</z:e> in subjects with <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> or <z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">mood disorder</z:e>, the exclusion of these patients in neuropsychological studies may not be systematically justified </plain></SENT>
</text></document>